Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 290.91 percent. This is a 530 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $37.568 million which beat the analyst consensus estimate of $27.119 million by 38.53 percent. This is a 98.48 percent increase over sales of $18.928 million the same period last year.